Literature DB >> 18393604

Rotavirus vaccine introduction in the Americas: progress and lessons learned.

Lucia Helena de Oliveira1, M Carolina Danovaro-Holliday, Cuauhtemoc Ruiz Matus, Jon Kim Andrus.   

Abstract

In Latin America and the Caribbean, rotavirus causes approximately 15,000 deaths, 75,000 hospitalizations, 2 million clinic visits and 10 million cases of rotavirus diarrhea annually. Two safe vaccines are available that are effective in preventing severe illness. To date, seven countries in Latin America (Brazil, Ecuador, El Salvador, Panama, Mexico, Nicaragua and Venezuela) have introduced the vaccine. For successful rotavirus vaccine introduction, the lessons learned re-emphasize the critical need for countries to have precise plans that will ensure technical, programmatic and financial sustainability of vaccine introduction. Of these lessons learned, programmatic feasibility and financial sustainability were particularly challenging for countries that were the first to introduce a rotavirus vaccine.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18393604     DOI: 10.1586/14760584.7.3.345

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  24 in total

1.  Impact of introducing the pneumococcal and rotavirus vaccines into the routine immunization program in Niger.

Authors:  Bruce Y Lee; Tina-Marie Assi; Jayant Rajgopal; Bryan A Norman; Sheng-I Chen; Shawn T Brown; Rachel B Slayton; Souleymane Kone; Hailu Kenea; Joel S Welling; Diana L Connor; Angela R Wateska; Anirban Jana; Ann E Wiringa; Willem G Van Panhuis; Donald S Burke
Journal:  Am J Public Health       Date:  2011-11-28       Impact factor: 9.308

Review 2.  Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developing countries.

Authors:  Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2011-11       Impact factor: 4.981

3.  How influenza vaccination policy may affect vaccine logistics.

Authors:  Tina-Marie Assi; Korngamon Rookkapan; Jayant Rajgopal; Vorasith Sornsrivichai; Shawn T Brown; Joel S Welling; Bryan A Norman; Diana L Connor; Sheng-I Chen; Rachel B Slayton; Yongjua Laosiritaworn; Angela R Wateska; Stephen R Wisniewski; Bruce Y Lee
Journal:  Vaccine       Date:  2012-04-24       Impact factor: 3.641

4.  Cost-effectiveness of a new rotavirus vaccination program in Pakistan: a decision tree model.

Authors:  Hiten D Patel; Eric T Roberts; Dagna O Constenla
Journal:  Vaccine       Date:  2013-10-29       Impact factor: 3.641

Review 5.  Performance of rotavirus vaccines in developed and developing countries.

Authors:  Victoria Jiang; Baoming Jiang; Jacqueline Tate; Umesh D Parashar; Manish M Patel
Journal:  Hum Vaccin       Date:  2010-07

Review 6.  The impact of new vaccine introduction on immunization and health systems: a review of the published literature.

Authors:  Terri B Hyde; Holly Dentz; Susan A Wang; Helen E Burchett; Sandra Mounier-Jack; Carsten F Mantel
Journal:  Vaccine       Date:  2012-08-29       Impact factor: 3.641

Review 7.  Rotavirus infections and vaccines: burden of illness and potential impact of vaccination.

Authors:  Keith Grimwood; Stephen B Lambert; Richard J Milne
Journal:  Paediatr Drugs       Date:  2010-08-01       Impact factor: 3.022

8.  Enhancing the work of the Department of Health and Human Services national vaccine program in global immunization: recommendations of the National Vaccine Advisory Committee: approved by the National Vaccine Advisory Committee on September 12, 2013.

Authors: 
Journal:  Public Health Rep       Date:  2014       Impact factor: 2.792

Review 9.  Constructing target product profiles (TPPs) to help vaccines overcome post-approval obstacles.

Authors:  Bruce Y Lee; Donald S Burke
Journal:  Vaccine       Date:  2009-09-25       Impact factor: 3.641

10.  Potential safety issues and other factors that may affect the introduction and uptake of rotavirus vaccines.

Authors:  N Aliabadi; J E Tate; U D Parashar
Journal:  Clin Microbiol Infect       Date:  2016-04-26       Impact factor: 8.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.